Turning Point Brands carries a Neutral rating, with a composite score of 56 out of 100 and a conviction reading of 2 of 5. Fundamentals carry 35 percent of the model, regulatory posture 25, market signal 25, and editorial density 15, with every pillar contribution auditable. Fundamentals leads the pillar table at 83, and is the main lever behind the Neutral conclusion. The offset comes from editorial at 30, which pulls the composite toward the middle of the band.
The scoring inputs are concrete: reported revenue growth of 16.8 percent year over year, an operating margin of 10.3 percent, a market cap near 1.7 billion. Together they explain most of the pillar mix. All inputs are drawn from primary regulatory filings, licensed fundamentals data, institutional pricing feeds, and CIN newsroom coverage density. Because every ticker in the CIN universe is scored on the same 336-name basis, Turning Point Brands slots into a direct comparison rather than a bespoke narrative, and the score refreshes on the primary-source ingest cadence.
The next quarterly release stands as the primary catalyst, since fundamentals drive 83 of the composite. A revenue print above the trailing four-quarter average combined with a stable operating margin would justify a step toward the upper band edge, while a miss on either would erode the Neutral anchor.
Bullish and Bearish Analyst Opinions for Turning Point Brands (TPB)
Cannabis Investor News aggregates analyst coverage, price targets, insider transactions, SEC filings, and financing activity for Turning Point Brands (TPB), a cannabis-sector equity listed on NYSE. Use this profile to compare bullish and bearish opinions, monitor Form 4 insider buys and sells, and review the latest quarterly results.
Bullish and bearish analyst opinions for Turning Point Brands, Inc. (TPB)
Bullish view. Turning Point Brands' Zig-Zag core generates steady free cash flow, and analysts covering the name typically highlight the FRE ('free-cash-flow') margin resilience across tobacco-cycle downturns.
Bearish view. Skeptics focus on the declining vape and moist-snuff exposure inside its NewGen segment and periodic regulatory friction on nicotine substitutes.
5-year weekly price history, intraday quotes, and 52-week range for TPB are maintained by Cannabis Investor News and refreshed throughout the trading day.